Short description
A clinical stage drug development company who aims to invent novel drugs for hard-to-treat diseases using its proprietary AI platform
Description
Auransa is a clinical stage drug development company who aims to invent high value, novel drugs for hard-to-treat diseases like cancer, auto-immune and neurological disorders using its proprietary AI platform and drug discovery expertise. The company's platform is used to understand biology of diseases at subtype level resolution, enabling it to predict compounds and targets of novel pharmacology for responder patient population. Current internal drug pipeline includes a first-in-class investigational new drug for cancer in clinical trials. Auransa has partnership with companies and institutions in the biopharma industry.
Last funding
Absolutely Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Palo Alto, California, United States, North America
Founded on
January 1, 2014
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Cannot Access, Uh Ohhhh, Cannot Access, Noaccess, Noaccess, Noaccess
Sign in for full access
Founders
Pek Lum, Viwat Visuthikraisee